Home Ingredients D-Mannose
Kidney/Urinary TractWomen's Health

D-Mannose

Evidence Level
Moderate
3 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

D-Mannose is a simple sugar closely related to glucose, found naturally in fruits such as cranberries, peaches, and apples. Although chemically a monosaccharide, only a small fraction is metabolized for energy — most is excreted unchanged in the urine, where it can bind to type 1 fimbriae of uropathogenic Escherichia coli and help prevent the bacteria from adhering to the bladder wall. This anti-adhesion mechanism has made D-mannose a popular non-antibiotic option for women with recurrent urinary tract infections. The evidence base includes a landmark 2014 randomized trial, several smaller positive studies, and a larger 2024 UK primary-care MERIT trial that did not find benefit over placebo — making the overall picture mixed but clinically meaningful for some users.

Studied Dose 2 g once daily for prophylaxis (most studied); 1.5-3 g daily in symptomatic protocols, dissolved in water.
Active Compound D-Mannose, a six-carbon monosaccharide (C6H12O6) and C2 epimer of glucose, typically supplied as 95-100% pure powder or capsules.

Benefits

Helps Support Urinary Tract Health

D-mannose helps support a healthy urinary environment by binding to E. coli fimbriae in the urine, which may help reduce the bacteria's ability to attach to the bladder wall — a key mechanism in recurrent urinary tract concerns.

Supported by Trial 2, Trial 3

Non-Antibiotic Daily Option

For women looking to reduce reliance on long-term antibiotic prophylaxis, D-mannose offers a non-antibiotic, sugar-based option that has been evaluated in randomized trials with a strong tolerability profile.

Supported by Trial 1, Trial 3

Generally Well-Tolerated Daily Use

Even at gram-level daily doses for six months in clinical work, D-mannose has shown a favorable safety profile, with only mild GI effects reported and no meaningful impact on blood glucose in non-diabetic adults.

Supported by Trial 1, Trial 2

Convenient Powder Format

D-mannose dissolves readily in water with a slightly sweet taste, making it easy to take consistently — convenience is a significant factor in real-world adherence to UTI-prevention regimens.

Supported by Trial 1, Trial 2

Mechanism of action

1

FimH Anti-Adhesion in the Bladder

Uropathogenic E. coli use the FimH adhesin on type 1 fimbriae to bind mannosylated receptors on the urothelium. Excreted urinary D-mannose saturates FimH, helping flush bacteria out during urination rather than allowing colonization.

2

Minimal Systemic Metabolism

Only a small fraction of ingested D-mannose is metabolized; the majority is filtered by the kidneys and concentrated in the urine, where it can interact with bacterial adhesins at meaningful local concentrations.

3

No Direct Antibacterial Action

D-mannose does not kill bacteria — it works mechanically by preventing attachment. This avoids antimicrobial selection pressure and theoretically limits resistance development.

Clinical trials

1
D-Mannose vs Nitrofurantoin Prophylaxis

Open-label randomized trial; 2 g D-mannose/day vs 50 mg nitrofurantoin/day vs no prophylaxis for 6 months

308 women with history of recurrent UTI

Six-month UTI recurrence was significantly lower in both the D-mannose and antibiotic arms than in no-prophylaxis controls, with D-mannose showing fewer adverse events than the antibiotic — supporting its use as a non-antibiotic prevention option.

2
D-Mannose Pilot in Acute Cystitis

Open-label pilot study; 1.5 g D-mannose daily for acute cystitis treatment plus extended follow-up

45 women with acute, uncomplicated cystitis

D-mannose was associated with reductions in lower urinary tract symptoms and a lower rate of UTI recurrence over six-month follow-up; a hypothesis-generating pilot rather than a definitive trial.

3
MERIT Trial: D-Mannose for Prevention in UK Primary Care

Pragmatic, double-blind, placebo-controlled RCT; 2 g D-mannose daily vs placebo for 6 months

598 women presenting to UK primary care with recurrent UTI (mean age 58)

Daily D-mannose did not significantly reduce the proportion of women experiencing a subsequent clinically suspected UTI compared with placebo; trial authors concluded D-mannose should not be routinely recommended for primary-care prophylaxis in this group.

Side effects and drug interactions

Common Potential side effects

Mild diarrhea or loose stools can occur, particularly at higher gram-level doses.
Bloating or abdominal discomfort is occasionally reported.
Theoretical caution in poorly controlled diabetes due to the sugar load.
Not a substitute for antibiotic therapy in established, symptomatic infection.

Important Drug interactions

No major drug-drug interactions are well documented for D-mannose.
May affect glycemic monitoring slightly in people with diabetes.
Discuss with a clinician before substituting for prescribed UTI prophylaxis.

More Kidney/Urinary Tract Ingredients

Gut Health
Magnesium Citrate
Magnesium citrate is magnesium combined with citric acid — among the most bioavailable for…
Bone Health
Calcium Citrate
Calcium citrate is calcium combined with citric acid — distinguished by absorption that DO…
Cardiovascular
Potassium Citrate
Potassium citrate is potassium combined with citric acid — distinct from potassium chlorid…
Men's Health
Pygeum (African Plum / Prunus Africana)
Pygeum africanum (African plum) bark extract is one of the most-studied herbal interventio…

Frequently asked questions about D-Mannose

What is the recommended dosage of D-Mannose?

The clinically studied dose for D-Mannose is 2 g once daily for prophylaxis (most studied); 1.5-3 g daily in symptomatic protocols, dissolved in water.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is D-Mannose used for?

D-Mannose is studied for helps support urinary tract health, non-antibiotic daily option, generally well-tolerated daily use. D-mannose helps support a healthy urinary environment by binding to E. coli fimbriae in the urine, which may help reduce the bacteria's ability to attach to the bladder wall — a key mechanism in recurrent urinary tract concerns.

Are there side effects from taking D-Mannose?

Reported potential side effects may include: Mild diarrhea or loose stools can occur, particularly at higher gram-level doses. Bloating or abdominal discomfort is occasionally reported. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does D-Mannose interact with medications?

Known drug interactions may include: No major drug-drug interactions are well documented for D-mannose. May affect glycemic monitoring slightly in people with diabetes. Consult a pharmacist or healthcare provider if you take prescription medications.

Is D-Mannose good for kidney/urinary tract?

Yes, D-Mannose is researched for Kidney/Urinary Tract support. D-mannose helps support a healthy urinary environment by binding to E. coli fimbriae in the urine, which may help reduce the bacteria's ability to attach to the bladder wall — a key mechanism in recurrent urinary tract concerns.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79-84. doi: 10.1007/s00345-013-1091-6.PubMedUsed to support: Open-label RCT of 308 women showing 2 g/day D-mannose reduced 6-month UTI recurrence comparably to nitrofurantoin and significantly better than no prophylaxis.
  2. Domenici L, Monti M, Bracchi C, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016;20(13):2920-5.PubMedUsed to support: Open-label pilot in 45 women showing D-mannose reduced lower urinary tract symptoms and UTI recurrence over 6-month follow-up.
  3. Hayward G, Mort S, Hay AD, et al. d-Mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial. JAMA Intern Med. 2024;184(6):619-628. doi: 10.1001/jamainternmed.2024.0264.PubMedUsed to support: Pragmatic 598-woman UK primary-care RCT (MERIT) in which daily 2 g D-mannose did not reduce clinically suspected UTI compared with placebo over 6 months.